Details
Stereochemistry | MIXED |
Molecular Formula | C17H24O3 |
Molecular Weight | 276.3707 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1CC(CC(C)(C)C1)OC(=O)C(O)C2=CC=CC=C2
InChI
InChIKey=WZHCOOQXZCIUNC-UHFFFAOYSA-N
InChI=1S/C17H24O3/c1-12-9-14(11-17(2,3)10-12)20-16(19)15(18)13-7-5-4-6-8-13/h4-8,12,14-15,18H,9-11H2,1-3H3
Cyclandelate is a vasodilator developed for the treatment of cardiovascular diseases. The drug was used in many countries for such diseases as intermittent claudication, arteriosclerosis obliterans, thrombophlebitis, nocturnal leg cramps, local frostbite, Raynaud's phenomenon. In the USA it was also approved for intermittent claudication and cognitive dysfunction in Alzheimer's disease under the name Cyclospasmol. Cyclandelate exerts its effect by blocking calcium channels and inhibiting smooth muscles contration. Cyclandelate was withdrawn from the market in the USA for lack of effectiveness.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363032 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CYCLOSPASMOL Approved UseA treatment for intermittent claudication and a treatment for cognitive
dysfunction in Alzheimer's disease. |
|||
Palliative | CYCLOSPASMOL Approved UseA treatment for intermittent claudication and a treatment for cognitive
dysfunction in Alzheimer's disease. |
Doses
Dose | Population | Adverse events |
---|---|---|
1600 mg 2 times / day multiple, oral Highest studied dose Dose: 1600 mg, 2 times / day Route: oral Route: multiple Dose: 1600 mg, 2 times / day Co-administed with:: Cholestyramine, p.o(16g, b.i.d) Sources: Page: p.132 |
unhealthy, 36 - 60 n = 10 Health Status: unhealthy Condition: Familial hypercholesterolaemia Age Group: 36 - 60 Sex: M+F Population Size: 10 Sources: Page: p.132 |
PubMed
Title | Date | PubMed |
---|---|---|
Screening for new compounds with antiherpes activity. | 1984 Oct |
|
Quinine blindness. | 1992 Dec |
|
Cyclandelate in the prophylaxis of migraine: a placebo-controlled study. | 2001 Feb |
|
Inhibition of purified pig and human liver retinyl ester hydrolase by pharmacologic agents. | 2001 May |
|
Chiral separation of several drugs using electrophoresis with dual cyclodextrin systems. | 2002 Sep |
|
Vasospastic amaurosis fugax. | 2003 Feb |
|
Metabolism of ciclesonide in the upper and lower airways: review of available data. | 2008 Sep 7 |
|
Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project. | 2010 |
|
Anthroposophic therapy for migraine: a two-year prospective cohort study in routine outpatient settings. | 2010 |
|
Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. | 2010 Sep 29 |
Patents
Sample Use Guides
The usual dose of cyclandelaye is between 400 - 800 mg per day, given in two or four divided doses. If indicated, higher doses of 1200 mg to 1600 mg per day may be given in four divided doses before meals and at bedtime, for two to four weeks, and then reduced by 200 mg decrements to the usual dose.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3622308
Cyclandelate in concentrations between 10 and 50 uM induced a dose-dependent increase in the basal level of cytosolic Ca++ of unstimulated platelets. In platelets stimulated with thrombin (5 U/ml) or platelet activating factor (1 uM), cyclandelate strongly inhibited the increase of cystolic Ca++ in the presence of extracellular Ca++, but in the absence of extracellular Ca++ only a weak inhibition was observed. This inhibition was dose dependent and optimal at about 50 uM, the concentration at which Ca++ mobilisation was suppressed to about 10% of control values, and at which cyclandelate inhibits platelet aggregation.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
||
|
LIVERTOX |
245
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
||
|
WHO-VATC |
QC04AX01
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
||
|
WHO-ATC |
C04AX01
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
456-59-7
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
4139O1OAY2
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
CYCLANDELATE
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
1152701
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
100000092568
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
SUB06841MIG
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
2893
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
3988
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
DTXSID4022862
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
D003495
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
2970
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | RxNorm | ||
|
DB04838
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
747
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
3046
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
207-271-6
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL1480987
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
758910
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
821
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
C77072
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | |||
|
m3967
Created by
admin on Sat Dec 16 10:47:29 GMT 2023 , Edited by admin on Sat Dec 16 10:47:29 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY